New use of melagatran
AssigneeAstraZeneca AB
InventorIan Kirk
Life of this patent
Estimating the term…
Abstract
According to the invention there is provided the use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of a medicament for the treatment of inflammation.
Claims11
The use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of a medicament for the treatment of inflammation.
The use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of an antiinflammatory medicament.
A method of treatment of inflammation which comprises administering a therapeutically effective amount of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, to a patient in need of such treatment.
A pharmaceutical formulation for use in the treatment of inflammation comprising an effective amount of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof.
Use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, for the treatment of inflammation by administering melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, to a patient.
The use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the treatment of inflammation.
A use, method or formulation as claimed in any one of the preceding claims, wherein the prodrug is the formula
- R1O2C—CH2—(R)Cgl-Aze-Pab-OH
- wherein R1 represents linear or branched C1-6 alkyl and the OH group replaces one of the amidino hydrogens in Pab.
Dependencies are inferred from the claim text.